Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC 50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2). In Vivo Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the C max , AUC 0-24h , t 1/2 and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours and 35.5%, respectively . Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t 1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Sprague−Dawley (SD) rats (180-220 g) Dosage: 3 mg/kg Administration: p.o. (Pharmacokinetic Analysis) Result: The C max , AUC 0-24h , t 1/2 and F were 0.27 μg/mL, 6.2 μg h/mL, 7.7 hours and 35.5%, respectively. Form:Solid